Tag - ATH

Developments

USPTO grants Alterity new composition of matter patent

Alterity Therapeutics (ASX: ATH; NASDAQ: ATHE) has announced that the United States Patent and Trademark Office (USPTO) has granted a new composition of matter patent for the company’s lead clinical asset, ATH434, an...

August 12, 2026

Developments

Alterity underscores published data on role of iron in neurodegenerative diseases

Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has highlighted a peer-reviewed article published in Metallomics, emphasizing the significance of iron and iron-targeting agents, such as the company’s ATH434, in treating...

November 6, 2024

Tag - ATH

USPTO grants Alterity new composition of matter patent

Alterity underscores published data on role of iron in neurodegenerative diseases

Subscribe